Breaking News Instant updates and real-time market news.

2022-05-19 09:26:53 GDS GDS Holdings $27.13 / -3.31 (-10.87%) 09:26 05/19/22 05/19 09:26 05/19/22 09:26	GDS Holdings reports Q1 EPS (50c), consensus (25c) Reports Q1 revenue $353.1M, consensus $340.1M. "We kicked off 2022 with a solid first quarter," said Mr.William Huang, CEO. "During the first quarter, we secured over 18,000 sqm of new bookings and further cemented our leading position in China's Tier 1 markets through both organic and acquisition-driven growth. In addition, we progressed our regionalization plan to deepen our presence in Southeast Asia through our partnership with YTL for green data center campus development in Malaysia, creating a unique platform with access to renewable energy in this emerging digital region."

2022-05-19 09:26:53

GDS

GDS Holdings

$27.13 / -3.31 (-10.87%)

09:26

05/19/22

05/19

09:26

05/19/22

09:26

GDS Holdings reports Q1 EPS (50c), consensus (25c)

Reports Q1 revenue $353.1M, consensus $340.1M. "We kicked off 2022 with a solid first quarter," said Mr.William Huang, CEO. "During the first quarter, we secured over 18,000 sqm of new bookings and further cemented our leading position in China's Tier 1 markets through both organic and acquisition-driven growth. In addition, we progressed our regionalization plan to deepen our presence in Southeast Asia through our partnership with YTL for green data center campus development in Malaysia, creating a unique platform with access to renewable energy in this emerging digital region."

OTHER BREAKING NEWS FROM THE FLY

Upgrade	Deutsche Bank raises Sanofi to Hold, calls Zantac 'knee-jerk' reaction overdone » 08:15 08/12/22 08/12 08:15 08/12/22 08:15 SNY Sanofi $43.46 / -1.74 (-3.85%) As previously reported,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events SNY Sanofi $43.46 / -1.74 (-3.85%) 08/11/22 Sanofi says 'confident in its legal defenses' related to U.S. Zantac litigation 08/04/22 Sanofi announces strategic collaboration with Innovent Biologics 07/21/22 Innate Pharma announces Sanofi decision to progress IPH6401/SAR'514 07/18/22 Editas Medicine appoints Mei as SVP, CMO SNY Sanofi $43.46 / -1.74 (-3.85%) 07:40 Today JPMorgan Sanofi may not be liable for any Zantac litigation damages, says JPMorgan 05:33 Today Deutsche Bank Sanofi upgraded to Hold from Sell at Deutsche Bank 08/11/22 JPMorgan Perrigo, Pfizer appear to have manageable Zantac exposure, says JPMorgan 08/11/22 Deutsche Bank Zantac cases likely a short-term headwind for GSK, Sanofi, says Deutsche Bank SNY Sanofi $43.46 / -1.74 (-3.85%) 07/28/22 Sanofi sees 2022 business EPS growing 15% at CER 07/28/22 Sanofi reports Q2 business EPS EUR 1.73, up 16.7% at CER 04/28/22 Sanofi still expects 2022 business EPS to grow low double-digit at CER 04/28/22 Sanofi reports Q1 business EPS EUR 1.94, up 16.1% at CER SNY Sanofi $43.46 / -1.74 (-3.85%) 08/11/22 GSK, Sanofi weakness related to Zantac litigation worries, Bloomberg reports SNY Sanofi $43.46 / -1.74 (-3.85%) 08/11/22 What You Missed On Wall Street On Thursday 08/11/22 Renewed Zantac litigation concerns sinking these big-cap drugmakers 08/11/22 What You Missed On Wall Street This Morning 06/24/22 What You Missed On Wall Street On Friday 09/10/22 ESMO Congress 2022
Earnings	Xenetic reports Q2 net loss $2.7M » 08:13 08/12/22 08/12 08:13 08/12/22 08:13 XBIO Xenetic / + The Company ended the… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research XBIO Xenetic / + 08/02/22 Xenetic, VolitionRx collaborate to develop NETs-targeted adoptive cell therapies 07/07/22 Xenetic enters manufacturing agreement with Catalent Pharma Solutions 07/07/22 Xenetic enters clinical manufacturing agreement with Catalent XBIO Xenetic / + 05/02/22 H.C. Wainwright Xenetic price target lowered to $4 from $5 at H.C. Wainwright
Recommendations	Pear Therapeutics price target lowered to $5 from $11 at BTIG » 08:12 08/12/22 08/12 08:12 08/12/22 08:12 PEAR Pear Therapeutics $2.25 / +0.27 (+13.64%) BTIG analyst Marie… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Options PEAR Pear Therapeutics $2.25 / +0.27 (+13.64%) 08/11/22 Pear Therapeutics reduced workforce on July 25 due to macro environment 08/10/22 Pear Therapeutics announces publication of insomnia analysis 08/08/22 Pear Therapeutics, SelectHealth announce reSET-O added as covered benefit 08/03/22 Pear, Cove Behavioral avail patients PDT reSET-O for opiod abuse treatment PEAR Pear Therapeutics $2.25 / +0.27 (+13.64%) 07:48 Today Chardan Pear Therapeutics price target lowered to $9 from $13 at Chardan 06/24/22 BTIG Pear Therapeutics price target lowered to $11 from $12 at BTIG 05/24/22 Cowen Pear Therapeutics revenues raised on strong Rx growth, says Cowen 05/17/22 Chardan Pear Therapeutics price target lowered to $13 from $16 at Chardan PEAR Pear Therapeutics $2.25 / +0.27 (+13.64%) 08/11/22 Pear Therapeutics reports Q2 EPS 4c, consensus (25c) 05/16/22 Pear Therapeutics backs FY22 revenue view $22M, consensus $21.06M 05/16/22 Pear Therapeutics reports Q1 EPS (17c), consensus (24c) 03/28/22 Pear Therapeutics sees FY22 revenue $22M, consensus $21.79M PEAR Pear Therapeutics $2.25 / +0.27 (+13.64%) 08/11/22 Fly Intel: After-Hours Movers 05/16/22 Fly Intel: After-Hours Movers PEAR Pear Therapeutics $2.25 / +0.27 (+13.64%) 05/11/22 Eighteen new option listings on May 11th
Recommendations	Plug Power price target raised to $29 from $19 at Wells Fargo » 08:12 08/12/22 08/12 08:12 08/12/22 08:12 PLUG Plug Power $27.74 / -1.04 (-3.61%) Wells Fargo analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Options PLUG Plug Power $27.74 / -1.04 (-3.61%) 08/04/22 New Fortress Energy enters 120MW green hydrogen plant deal with Plug Power 08/04/22 Plug Power selected by New Fortress Energy for 120 MW green hydrogen plant 07/29/22 Microsoft posts blog detailing work with partner Plug Power 07/12/22 Plug Power secures 5MW electrolyzer sale to Irving Oil PLUG Plug Power $27.74 / -1.04 (-3.61%) 08/11/22 Citi Plug Power price target raised to $36 from $20 at Citi 08/11/22 Truist Plug Power price target raised to $32 from $21 at Truist 08/10/22 B. Riley Plug Power price target raised to $32 from $31 at B. Riley 08/10/22 Cowen Plug Power price target lowered to $35 from $44 at Cowen PLUG Plug Power $27.74 / -1.04 (-3.61%) 08/09/22 Plug Power reports Q2 EPS (30c) vs. (18c) last year 08/09/22 Notable companies reporting after market close 05/09/22 Plug Power reports Q1 EPS (27c), consensus (16c) 05/09/22 Notable companies reporting after market close PLUG Plug Power $27.74 / -1.04 (-3.61%) 08/09/22 Fly Intel: After-Hours Movers 08/08/22 What You Missed This Week in EVs and Clean Energy 06/13/22 What You Missed This Week in EVs and Clean Energy 06/08/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations PLUG Plug Power $27.74 / -1.04 (-3.61%) 07/28/22 Unusually active option classes on open July 28th 07/06/22 Plug Power call volume above normal and directionally bullish 06/27/22 Plug Power put volume heavy and directionally bearish 05/09/22 Unusually active option classes on open May 9th
Hot Stocks	Guardant Health receives FDA approval Guardant360 CDx liquid biopsy test as CDx » 08:11 08/12/22 08/12 08:11 08/12/22 08:11 GH Guardant Health $53.10 / +0.03 (+0.06%) , AZN AstraZeneca $64.66 / -1.175 (-1.78%) Guardant Health (GH)… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options GH AZN GH Guardant Health $53.10 / +0.03 (+0.06%) 08/02/22 Guardant Health announces Medicare coverage for Guardant Reveal test 07/06/22 Guardant Health, Adicon Holdings announce CGP test partnership 06/13/22 Guardant Health completes purchase of AMEA joint venture 05/22/22 Guardant Health presents new data showing blood test accuracy in detecting CRC AZN AstraZeneca $64.66 / -1.175 (-1.78%) 06:23 Today AstraZeneca's Enherty approved in U.S. for NSCLC with ERBB2 mutations 08/11/22 AstraZeneca completes acquisition of TeneoTwo 08/09/22 Datopotamab deruxtecan combo shows 'promising clinical activity' in study 08/08/22 AstraZeneca, Hutchmed report results from SAVANNAH Phase II trial GH AZN GH Guardant Health $53.10 / +0.03 (+0.06%) 08/03/22 Citi Exact Sciences price target lowered to $50 from $65 at Citi 08/02/22 Piper Sandler Guardant Health coverage news 'notable positive,' says Piper Sandler 08/01/22 OTR Global Guardant Health view downgraded to Mixed from Positive at OTR Global 06/02/22 Piper Sandler Guardant Health initiated with an Overweight at Piper Sandler AZN AstraZeneca $64.66 / -1.175 (-1.78%) 08/05/22 Morgan Stanley AstraZeneca price target raised to 12,000 GBp from 11,500 GBp at Morgan Stanley 08/04/22 Barclays AstraZeneca price target lowered to 12,000 GBp from 12,500 GBp at Barclays 08/01/22 JPMorgan AstraZeneca price target raised to 12,500 GBp from 12,000 GBp at JPMorgan 08/01/22 Deutsche Bank AstraZeneca price target raised to 12,000 GBp from 11,500 GBp at Deutsche Bank GH AZN GH Guardant Health $53.10 / +0.03 (+0.06%) 08/04/22 Guardant Health backs FY22 revenue $460M-$470M, consensus $465.29M 08/04/22 Guardant Health reports Q2 adjusted EPS ($1.00), consensus ($1.21) 05/05/22 Guardant Health backs FY22 revenue view $460M-$470M, consensus $465.93M 05/05/22 Guardant Health reports Q1 adjusted EPS (91c), consensus ($1.21) AZN AstraZeneca $64.66 / -1.175 (-1.78%) 07/29/22 AstraZeneca backs FY22 core EPS view up by mid to high twenties percentage 07/29/22 AstraZeneca reports Q2 core EPS $1.72, up 89% year-over-year 04/29/22 AstraZeneca backs FY22 core EPS up by mid to high twenties percentage 04/29/22 AstraZeneca reports Q1 core EPS $1.89, up 20% y/y AZN AZN AstraZeneca $64.66 / -1.175 (-1.78%) 06/17/22 AstraZeneca considering bid for Mereo BioPharma, U.K. Times reports 05/10/22 Emergent plant's quality problems led to 400M discarded vaccines, WSJ reports 03/23/22 AstraZeneca preventive COVID shot set to win EU clearance, Reuters says AZN AZN AstraZeneca $64.66 / -1.175 (-1.78%) 07/05/22 Fly Intel: Pre-market Movers 05/24/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 04/06/22 Fly Intel: Pre-market Movers 03/23/22 What You Missed On Wall Street On Wednesday 08/29/22 Med Tech & Life Sciences West Coast Field Trip 09/10/22 ESMO Congress 2022 AZN AZN AstraZeneca $64.66 / -1.175 (-1.78%) 07/20/22 AstraZeneca call volume above normal and directionally bullish 06/06/22 Unusually active option classes on open June 6th 04/26/22 AstraZeneca call volume above normal and directionally bullish 04/07/22 AstraZeneca put volume heavy and directionally bearish
Hot Stocks	Kalera announces revised date for Q2 financial results » 08:10 08/12/22 08/12 08:10 08/12/22 08:10 KAL Kalera $2.93 / +0.19 (+6.93%) Kalera Public Limited… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Events KAL Kalera $2.93 / +0.19 (+6.93%) 06/30/22 Agrico Acquisition Corp trading resumes 06/30/22 Agrico Acquisition Corp trading halted, volatility trading pause 06/29/22 Kalera, Agrico Acquisition complete business combination KAL Kalera $2.93 / +0.19 (+6.93%) 07/07/22 Roth Capital Kalera initiated with a Buy at Roth Capital 08/15/22 Kalera - KAL
Hot Stocks	Rubicon sets record date for its $11 per share cash distribution » 08:09 08/12/22 08/12 08:09 08/12/22 08:09 RBCN Rubicon $16.10 / + (+0.00%) Rubicon Technology… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News RBCN Rubicon $16.10 / + (+0.00%) 07/05/22 Janel to launch cash tender offer to acquire 45% interest in Rubicon 05/10/22 Rubicon announces launch of RUBICONSelect
Recommendations	Rivian Automotive price target raised to $27 from $24 at DA Davidson » 08:09 08/12/22 08/12 08:09 08/12/22 08:09 RIVN Rivian Automotive $38.91 / +1.475 (+3.94%) DA Davidson analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Options RIVN Rivian Automotive $38.91 / +1.475 (+3.94%) 08/11/22 Rivian Automotive cuts FY22 adjusted EBITDA target to loss of $5.45B from $4.75B 08/11/22 Rivian Auto says supply chain constraints 'to remain limiting factor' in output 08/11/22 Rivian Automotive reports Q2 output of 4.40K and deliveries of 4.47K vehicles 08/11/22 Rivian Automotive affirms 2022 production target of 25K vehicles RIVN Rivian Automotive $38.91 / +1.475 (+3.94%) 07:02 Today Morgan Stanley Rivian Automotive's liqudity can last through most of FY23, says Morgan Stanley 06:44 Today Mizuho Rivian Automotive price target lowered to $65 from $70 at Mizuho 07/18/22 Deutsche Bank Rivian Automotive price target lowered to $46 from $69 at Deutsche Bank 07/13/22 Canaccord Rivian Automotive initiated with a Buy at Canaccord RIVN Rivian Automotive $38.91 / +1.475 (+3.94%) 08/11/22 Rivian Automotive reports Q2 EPS ($1.89), consensus ($1.67) 08/11/22 Notable companies reporting after market close 07/28/22 Amazon reports Q2 EPS (20c) with Rivian loss, consensus 13c 05/11/22 Rivian Automotive reports Q1 adjusted EPS ($1.43), consensus ($1.44) 10 Nov RIVN Rivian Automotive $38.91 / +1.475 (+3.94%) 08/02/22 Rivian says most vehicles ineligible under Senate climate deal, WSJ reports 07/27/22 Rivian cuts workforce by 6%, Bloomberg reports 07/27/22 Rivian cuts workforce by 6%, Bloomberg reports 07/12/22 Rivian plans all-hands meeting on Friday, CEO says in memo seen by Bloomberg RIVN Rivian Automotive $38.91 / +1.475 (+3.94%) 08/11/22 Fly Intel: After-Hours Movers 08/03/22 Here's what Wall Street experts are saying about these EV names ahead of results 08/02/22 What You Missed On Wall Street On Tuesday 08/01/22 What You Missed This Week in EVs and Clean Energy RIVN Rivian Automotive $38.91 / +1.475 (+3.94%) 08/11/22 Rivian options imply 8.3% move in share price post-earnings 07/13/22 Rivian call volume above normal and directionally bullish 07/06/22 Unusually active option classes on open July 6th 06/21/22 Rivian call volume above normal and directionally bullish
Hot Stocks	GrowGeneration CFO Jeff Lasher resigns, Greg Sanders succeeds » 08:08 08/12/22 08/12 08:08 08/12/22 08:08 GRWG GrowGeneration $5.62 / -0.335 (-5.63%) GrowGeneration announced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Options GRWG GrowGeneration $5.62 / -0.335 (-5.63%) 06/27/22 GrowGeneration announces 2022 annual meeting results 02/15/22 GrowGeneration selects Manhattan Active Point of Sale for omnichannel sales GRWG GrowGeneration $5.62 / -0.335 (-5.63%) 08/05/22 Alliance Global Partners GrowGeneration downgraded to Neutral from Buy at Alliance Global Partners 05/12/22 Oppenheimer GrowGeneration price target lowered to $15 from $50 at Oppenheimer 05/11/22 Wells Fargo GrowGeneration price target lowered to $4 from $8 at Wells Fargo 05/11/22 Alliance Global Partners GrowGeneration price target lowered to $7 from $14 at Alliance Global GRWG GrowGeneration $5.62 / -0.335 (-5.63%) 08/04/22 GrowGeneration cuts FY22 revenue view to $250M-$275M from $340M-$400M 08/04/22 GrowGeneration reports Q2 adjusted EPS (6c), consensus (8c) 05/11/22 GrowGeneration cuts FY22 revenue view to $340M-$400M, consensus $426.5M 05/10/22 GrowGeneration reports Q1 EPS (9c), consensus (8c) GRWG GrowGeneration $5.62 / -0.335 (-5.63%) 05/10/22 Fly Intel: After-Hours Movers 03/25/22 What You Missed On Wall Street On Friday 03/25/22 What You Missed On Wall Street This Morning GRWG GrowGeneration $5.62 / -0.335 (-5.63%) 07/25/22 Largest borrow rate increases among liquid names 05/16/22 Growgeneration call volume above normal and directionally bullish 04/14/22 Largest borrow rate increases among liquid names 04/05/22 Growgeneration call volume above normal and directionally bullish
Hot Stocks	XpresSpa announces re-opening of XpresSpa location at JFK Airport » 08:08 08/12/22 08/12 08:08 08/12/22 08:08 XSPA XpresSpa / + XpresSpa Group announced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Events Options XSPA XpresSpa / + 07/11/22 XpresSpa to open locations at Istanbul Airport in Turkey 06/14/22 XpresSpa names Haynes as interim CFO, Berry separation from company June 13 05/20/22 XpresSpa announces 10M share increase in stock repurchase 03/30/22 XpresSpa opens COVID-19 testing facility at Orlando International Airport XSPA XpresSpa / + 05/18/22 H.C. Wainwright XpresSpa price target lowered to $2 from $4 at H.C. Wainwright 03/16/22 H.C. Wainwright XpresSpa 'dislocation' brings buying opportunity, says H.C. Wainwright 11/17/21 H.C. Wainwright XpresSpa price target raised to $4 from $3.50 at H.C. Wainwright 08/15/22 XpresSpa - XSPA XSPA XpresSpa / + 04/12/22 Largest borrow rate increases among liquid names 04/08/22 Largest borrow rate increases among liquid names 03/28/22 Largest borrow rate increases among liquid names 03/15/22 XpresSpa options imply 18.0% move in share price post-earnings

Hot Stocks	Applied Blockchain secures $115M credit facility » 08:07 08/12/22 08/12 08:07 08/12/22 08:07 APLD Applied Blockchain $2.15 / +0.04 (+1.90%) Applied Blockchain… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events APLD Applied Blockchain $2.15 / +0.04 (+1.90%) 08/01/22 Applied Blockchain appoints Regina Ingel as CMO 07/18/22 Applied, Marathon enter hosting contract for 200-MW Bitcoin mining capacity 06/13/22 Applied Blockchain announces expiration of share lock-up 06/08/22 Applied Blockchain announces 5% reduction in outstanding common shares APLD Applied Blockchain $2.15 / +0.04 (+1.90%) 07/19/22 Lake Street Marathon contract gives Lake Street confidence in Applied Blockchain growth 05/23/22 Craig-Hallum Craig-Hallum bullish on Applied Blockchain, initiates with a Buy 05/23/22 Craig-Hallum Applied Blockchain initiated with a Buy at Craig-Hallum 05/09/22 Lake Street Applied Blockchain initiated with a Buy at Lake Street APLD Applied Blockchain $2.15 / +0.04 (+1.90%) 07/18/22 Applied Blockchain narrows Q4 revenue view to $5.95M-$7.2M, consensus $5.68M 13 Apr APLD Applied Blockchain $2.15 / +0.04 (+1.90%) 07/22/22 Here's What You Missed in Crypto This Week 05/23/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 05/09/22 What You Missed On Wall Street On Monday 05/09/22 What You Missed On Wall Street This Morning 09/14/22 6th Annual Best Ideas Growth Conference: Big 6
Downgrade	K+S AG downgraded to Sector Perform from Outperform at Scotiabank » 08:07 08/12/22 08/12 08:07 08/12/22 08:07 KPLUY K+S AG $10.87 / +0.28 (+2.64%) , NTR Nutrien $90.51 / +0.045 (+0.05%) , CF CF Industries $101.91 / +0.01 (+0.01%) Scotiabank analyst Ben… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options NTR CF NTR Nutrien $90.51 / +0.045 (+0.05%) 08/08/22 Nutrien name Ken Seitz as President and CEO 07/20/22 Nutrien to acquire Casa do Adubo, terms undisclosed 06/09/22 Nutrien announces plans to increase fertilizer production capacity 05/18/22 Denbury, Nutrien enter agreement for transportation and storage of CO2 CF CF Industries $101.91 / +0.01 (+0.01%) 07/18/22 CF Industries 'disappointed' by ITC injury determination on UAN imports 06/08/22 CF Industries to shut one of its U.K. manufacturing facilities 06/06/22 CF Industries exec Hoker sells 6,684 common shares 05/03/22 CF Industries, Mitsui announce plans for ammonia production facility in U.S. KPLUY NTR CF KPLUY K+S AG $10.87 / +0.28 (+2.64%) 07/18/22 Morgan Stanley K+S AG price target lowered to EUR 24 from EUR 26.50 at Morgan Stanley 05/12/22 Morgan Stanley K+S AG price target raised to EUR 26.50 from EUR 20.50 at Morgan Stanley 05/12/22 Scotiabank K+S AG price target raised to EUR 40 from EUR 38 at Scotiabank 04/20/22 DZ Bank K+S AG downgraded to Hold from Buy at DZ Bank NTR Nutrien $90.51 / +0.045 (+0.05%) 08/10/22 Barclays Nutrien price target lowered to $105 from $126 at Barclays 08/09/22 Scotiabank Nutrien upgraded to Outperform from Sector Perform at Scotiabank 07/18/22 RBC Capital ITC ruling against U.S. UAN tariffs negative for CF Industries, says RBC Capital 07/14/22 Credit Suisse Nutrien initiated with an Underperform at Credit Suisse CF CF Industries $101.91 / +0.01 (+0.01%) 08/10/22 Barclays CF Industries upgraded to Overweight from Equal Weight at Barclays 08/03/22 Scotiabank CF Industries upgraded to Outperform from Sector Perform at Scotiabank 08/03/22 Citi CF Industries upgraded to Buy on tighter ag conditions at Citi 08/03/22 Citi CF Industries upgraded to Buy from Neutral at Citi NTR CF NTR Nutrien $90.51 / +0.045 (+0.05%) 08/03/22 Nutrien cuts FY22 EPS view to $15.80-$17.80 from $16.20-$18.70 08/03/22 Nutrien reports Q2 EPS $6.51, consensus $5.76 05/02/22 Nutrien raises FY22 EPS view to $16.20-$18.70 from $10.20-$11.80 05/02/22 Nutrien reports Q1 EPS $2.70, consensus $2.72 CF CF Industries $101.91 / +0.01 (+0.01%) 08/01/22 CF Industries reports Q2 EPS $5.58, consensus $6.12 08/01/22 Notable companies reporting after market close 05/04/22 CF Industries reports Q1 EPS $4.21, consensus $4.35 02/15/22 CF Industries reports Q4 EPS $3.27, consensus $3.51 CF CF CF Industries $101.91 / +0.01 (+0.01%) 03/22/22 Agriculture stocks see increased demand amid Ukraine turmoil, Bloomberg says NTR CF NTR Nutrien $90.51 / +0.045 (+0.05%) 08/09/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 06/28/22 What You Missed On Wall Street This Morning 06/01/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 05/03/22 Fly Intel: Pre-market Movers CF CF Industries $101.91 / +0.01 (+0.01%) 08/10/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 08/03/22 What You Missed On Wall Street On Wednesday 08/03/22 What You Missed On Wall Street This Morning 08/03/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 11/03/22 Nutrien - NTR NTR CF NTR Nutrien $90.51 / +0.045 (+0.05%) 06/23/22 Nutrien put volume heavy and directionally bearish 06/10/22 Nutrien put volume heavy and directionally bearish 06/03/22 Nutrien put volume heavy and directionally bearish 05/12/22 Nutrien call volume above normal and directionally bullish CF CF Industries $101.91 / +0.01 (+0.01%) 08/01/22 CF Industries options imply 5.1% move in share price post-earnings 07/18/22 CF Industries put volume heavy and directionally bearish 07/15/22 Unusually active option classes on open July 15th 07/14/22 CF Industries put volume heavy and directionally bearish
Hot Stocks	SciSparc issued Israeli patent for tech treating CNS disorders » 08:07 08/12/22 08/12 08:07 08/12/22 08:07 SPRC SciSparc $1.19 / -0.025 (-2.06%) SciSparc announced it has… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News SPRC SciSparc $1.19 / -0.025 (-2.06%) 08/08/22 SciSparc announces Israeli Ministry of Health approval for ASD trial 08/01/22 SciSparc signs clinical trial agreement with Yale University 07/08/22 SciSparc to expand clinical operation to include U.S. site towards SCI-110 trial 07/07/22 SciSparc's JV MitoCareX Bio launches new laboratory facility in Israel
Recommendations	AppLovin price target lowered to $70 from $80 at DA Davidson » 08:06 08/12/22 08/12 08:06 08/12/22 08:06 APP AppLovin $34.46 / -6.01 (-14.85%) , U Unity $54.30 / -1.21 (-2.18%) DA Davidson analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Options APP U APP AppLovin $34.46 / -6.01 (-14.85%) 08/10/22 AppLovin drops 10% to $36.55 after reporting Q2 losses 08/09/22 ironSource drops 10% as AppLovin's Unity bid contingent on ironSource deal exit 08/09/22 AppLovin submits proposal to combine with Unity 08/09/22 AppLovin says proposal to combine would value Unity at $58.85 per share U Unity $54.30 / -1.21 (-2.18%) 08/11/22 Unity wins three-year contract from CACI 08/09/22 ironSource drops 10% as AppLovin's Unity bid contingent on ironSource deal exit 08/09/22 AppLovin submits proposal to combine with Unity 08/09/22 AppLovin says proposal to combine would value Unity at $58.85 per share APP U APP AppLovin $34.46 / -6.01 (-14.85%) 08/11/22 BTIG AppLovin price target lowered to $53 from $60 at BTIG 08/11/22 Truist AppLovin price target lowered to $65 from $77 at Truist 08/11/22 Credit Suisse ironSource downgraded to Neutral from Outperform at Credit Suisse 08/10/22 Citi AppLovin bid for Unity faces 'several challenges,' says Citi U Unity $54.30 / -1.21 (-2.18%) 08/11/22 Credit Suisse ironSource downgraded to Neutral from Outperform at Credit Suisse 08/10/22 Citi AppLovin bid for Unity faces 'several challenges,' says Citi 08/10/22 Oppenheimer Unity price target raised to $60 from $54 at Oppenheimer 08/10/22 Benchmark Benchmark keeps Sell rating on Unity, doesn't think AppLovin acquires APP U APP AppLovin $34.46 / -6.01 (-14.85%) 08/10/22 AppLovin sees FY22 revenue $2.84B-$3.14B, consensus $3.29B 08/10/22 AppLovin reports Q2 EPS (6c), consensus 18c 08/10/22 Notable companies reporting after market close 08/09/22 AppLovin lowers FY22 revenue view to $2.84B-$3.14B from $3.14B-$3.44B U Unity $54.30 / -1.21 (-2.18%) 08/09/22 Unity sees FY22 revenue $1.3B-$1.35B, consensus $1.36B 08/09/22 Unity sees Q3 revenue $315M-$335M, consensus $346.87M 08/09/22 Unity reports Q2 EPS (18c), consensus (21c) 08/09/22 Notable companies reporting after market close 03 Dec APP U APP AppLovin $34.46 / -6.01 (-14.85%) 06/30/22 AppLovin cuts 12% of workforce, AdExchanger reports U Unity $54.30 / -1.21 (-2.18%) 08/02/22 Unity in talks to spin off China unit, Reuters reports 06/29/22 Unity lays off hundreds of workers, Kotaku reports APP U APP AppLovin $34.46 / -6.01 (-14.85%) 08/11/22 What You Missed On Wall Street On Thursday 08/11/22 What You Missed On Wall Street This Morning 08/10/22 Fly Intel: After-Hours Movers 08/10/22 #SocialStocks: Musk sells Tesla shares should he lose legal battle with Twitter U Unity $54.30 / -1.21 (-2.18%) 08/10/22 #SocialStocks: Musk sells Tesla shares should he lose legal battle with Twitter 08/09/22 Fly Intel: After-Hours Movers 08/09/22 What You Missed On Wall Street On Tuesday 08/09/22 What You Missed On Wall Street This Morning APP U APP AppLovin $34.46 / -6.01 (-14.85%) 08/10/22 Applovin options imply 8.4% move in share price post-earnings 08/10/22 Largest borrow rate increases among liquid names 08/02/22 Largest borrow rate increases among liquid names 05/24/22 Applovin call volume above normal and directionally bullish U Unity $54.30 / -1.21 (-2.18%) 07/25/22 Unity Software put volume heavy and directionally bearish 07/12/22 Unity Software put volume heavy and directionally bearish 07/08/22 Unity Software call volume above normal and directionally bullish 06/16/22 Unity Software call volume above normal and directionally bullish
Hot Stocks	Terns Pharmaceuticals announces $65M oversubscribed offering » 08:06 08/12/22 08/12 08:06 08/12/22 08:06 TERN Terns Pharmaceuticals $2.40 / +0.14 (+6.19%) Terns Pharmaceuticals… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly TERN Terns Pharmaceuticals $2.40 / +0.14 (+6.19%) 06/01/22 Terns Pharmaceuticals appoints Kerry Russell as chief medical officer 05/16/22 Terns Pharmaceuticals expects cash to fund operations into 2025 03/21/22 Terns Pharmaceuticals announces Part 1 of AVIATION trial met primary endpoint TERN Terns Pharmaceuticals $2.40 / +0.14 (+6.19%) 03/23/22 JPMorgan Terns downgraded after 'firmly negative' data at JPMorgan 03/23/22 JPMorgan Terns Pharmaceuticals downgraded to Neutral from Overweight at JPMorgan 09/14/21 Goldman Sachs Terns Pharmaceuticals assumed with a Buy at Goldman Sachs TERN Terns Pharmaceuticals $2.40 / +0.14 (+6.19%) 05/16/22 Terns Pharmaceuticals reports Q1 EPS (55c), consensus (64c) 03/03/22 Terns Pharmaceuticals reports Q4 EPS (56c), consensus (63c) TERN Terns Pharmaceuticals $2.40 / +0.14 (+6.19%) 03/23/22 What You Missed On Wall Street On Wednesday 03/23/22 What You Missed On Wall Street This Morning 03/23/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
Hot Stocks	Vontier appoints Anshooman Aga as CFO » 08:05 08/12/22 08/12 08:05 08/12/22 08:05 VNT Vontier $24.16 / -0.315 (-1.29%) , HSC Harsco $6.56 / +0.04 (+0.61%) Vontier (VNT) announced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events VNT HSC VNT Vontier $24.16 / -0.315 (-1.29%) 07/28/22 Vontier names Hani Joakim as Chief Technology Officer 07/19/22 Watts Water names Andre Dhawa Chief Operating Officer 02/22/22 Vontier announces $250M accelerated share repurchase agreement HSC Harsco $6.56 / +0.04 (+0.61%) 06:17 Today Harsco CFO Anshooman Aga stepping down, Pete Minan named Interim CFO 07/28/22 Clean Earth opens new 10-day hazardous waste transfer facility in Puerto Rico 07/15/22 Harsco falls -18.9% 07/15/22 Harsco falls -17.1% VNT HSC VNT Vontier $24.16 / -0.315 (-1.29%) 07/08/22 Barclays Vontier price target lowered to $33 from $39 at Barclays 04/04/22 Barclays Vontier price target lowered to $40 from $42 at Barclays 03/23/22 Argus Vontier price target lowered to $30 from $40 at Argus 02/18/22 Citi Vontier price target lowered to $34 from $39 at Citi HSC Harsco $6.56 / +0.04 (+0.61%) 07/20/22 DA Davidson Harsco price target lowered to $13 from $16 at DA Davidson 07/18/22 Barrington Harsco price target lowered to $13 from $20 at Barrington 07/12/22 BMO Capital Harsco initiated with a Market Perform at BMO Capital 05/04/22 Barrington Harsco price target lowered to $20 from $22 at Barrington VNT HSC VNT Vontier $24.16 / -0.315 (-1.29%) 08/04/22 Vontier sees 2022 revenue $80M, consensus $3.19B 08/04/22 Vontier sees FY22 adjusted EPS $3.20-$3.30, consensus $3.24 08/04/22 Vontier sees Q3 adjusted EPS 85c-90c, consensus 91c 08/04/22 Vontier reports Q2 adjusted EPS 72c, consensus 70c HSC Harsco $6.56 / +0.04 (+0.61%) 08/02/22 Harsco lowers 2022 adjusted EPS view 0c-(13c) from 35c-45c, consensus 10c 08/02/22 Harsco sees Q3 adjusted EPS (2c)-(8c), consensus 6c 08/02/22 Harsco reports Q2 adjusted EPS 1c, consensus (1c) 07/15/22 Harsco sees FY22 GAAP operating loss of ($61M)-($51M) 09/14/22 6th Annual Best Ideas Growth Conference: Big 6
Earnings	Checkpoint Therapeutics reports Q2 EPS (16c), consensus (17c) » 08:05 08/12/22 08/12 08:05 08/12/22 08:05 CKPT Checkpoint Therapeutics $1.26 / +0.03 (+2.44%) Reports Q2 revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events Options CKPT Checkpoint Therapeutics $1.26 / +0.03 (+2.44%) 06/16/22 Checkpoint Therapeutics announces interim results from trial on cosibelimab 05/13/22 Checkpoint Therapeutics receives PIP waivers for cosibelimab from EMA CKPT Checkpoint Therapeutics $1.26 / +0.03 (+2.44%) 07/14/22 B. Riley Checkpoint Therapeutics resumed with a Buy at B. Riley 06/17/22 Lake Street Checkpoint cosibelimab data 'competitive,' says Lake Street 06/07/22 Lake Street Lake Street says Checkpoint warrants interest after cosibelimab 'shines' at ASCO 05/31/22 Cantor Fitzgerald Cantor sees 'positive' data likely coming from Checkpoint Therapeutics in June CKPT Checkpoint Therapeutics $1.26 / +0.03 (+2.44%) 05/12/22 Checkpoint Therapeutics reports Q1 EPS (20c), consensus (14c) 03/28/22 Checkpoint Therapeutics reports 2021 EPS (75c), consensus (51c) 09/14/22 6th Annual Best Ideas Growth Conference: Big 6 09/29/22 7th Annual Healthcare Conference CKPT Checkpoint Therapeutics $1.26 / +0.03 (+2.44%) 03/22/22 Checkpoint Therapeutics options imply 10.8% move in share price post-earnings 03/18/22 Checkpoint Therapeutics options imply 17.5% move in share price post-earnings 03/16/22 Checkpoint Therapeutics options imply 20.6% move in share price post-earnings
Hot Stocks	Longeveron expects cash to cover requirements into 1H24 » 08:04 08/12/22 08/12 08:04 08/12/22 08:04 LGVN Longeveron $5.96 / -0.17 (-2.77%) Cash and short-term… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events LGVN Longeveron $5.96 / -0.17 (-2.77%) 05/13/22 Longeveron sees cash, equivalents funding operations into 1H24 05/09/22 Longeveron CEO Geoff Green to resign 04/13/22 Longeveron enters into CRADA with US Department of VA 04/05/22 Longeveron appoints Min as Chief Medical Officer LGVN Longeveron $5.96 / -0.17 (-2.77%) 03/24/22 Maxim Maxim starts Longeveron at Buy, sees stock as 'inexpensive later-stage play' 03/24/22 Maxim Longeveron initiated with a Buy at Maxim 01/05/22 EF Hutton Longeveron initiated with a Buy at EF Hutton LGVN Longeveron $5.96 / -0.17 (-2.77%) 08:03 Today Longeveron reports Q2 EPS (27c), consensus (23c) 05/13/22 Longeveron reports Q1 EPS (17c) vs. (18c) last year 03/11/22 Longeveron reports Q4 EPS (20c), two est. (25c) LGVN Longeveron $5.96 / -0.17 (-2.77%) 04/05/22 Fly Intel: After-Hours Movers 08:30 Today Longeveron - LGVN
Downgrade	ResMed downgraded to Neutral at Citi on valuation » 08:04 08/12/22 08/12 08:04 08/12/22 08:04 RMD ResMed $241.21 / -2.37 (-0.97%) Citi analyst John… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Options RMD ResMed $241.21 / -2.37 (-0.97%) 08/11/22 ResMed increases quarterly dividend 5% to 44c per share 08/02/22 ResMed acquires mementor, terms undisclosed 07/25/22 Philips sees completion of Respironics field action by first quarter of 2023 07/25/22 Berkeley Lights appoints Mehul Joshi as CFO RMD ResMed $241.21 / -2.37 (-0.97%) 06:33 Today RBC Capital ResMed downgraded to Sector Perform at RBC Capital on valuation 06:18 Today RBC Capital ResMed downgraded to Sector Perform from Outperform at RBC Capital 06:18 Today Citi ResMed downgraded to Neutral from Buy at Citi 06/06/22 RBC Capital ResMed upgraded to Outperform from Sector Perform at RBC Capital RMD ResMed $241.21 / -2.37 (-0.97%) 08/11/22 ResMed reports Q4 EPS $1.49, consensus $1.34 04/28/22 ResMed reports Q3 EPS $1.32, consensus $1.42 RMD ResMed $241.21 / -2.37 (-0.97%) 03/24/22 Early notable gainers among liquid option names on March 24th
Earnings	VYNE Therapeutics reports Q2 adjusted EPS (13c) vs (35c) last year » 08:04 08/12/22 08/12 08:04 08/12/22 08:04 VYNE VYNE Therapeutics / + Reports Q2 revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings VYNE VYNE Therapeutics / + 08/10/22 VYNE announces Phase 2a trial of FMX144 did not meet primary endpoint 06/17/22 VYNE Therapeutics completes enrollment in Phase 2a trial of FMX114 05/10/22 VYNE Therapeutics hosting KOL even on InhiBET BET Inhibitor Platform 04/07/22 VYNE Therapeutics announces Phase 1b efficacy data for FMX114 VYNE VYNE Therapeutics / + 08/10/22 H.C. Wainwright VYNE Therapeutics price target lowered to $1.50 from $7 at H.C. Wainwright 01/13/22 Roth Capital Roth raises Journey Medical target to $17 after dermatology assets acquisition 12/06/21 H.C. Wainwright VYNE Therapeutics assumed with a Buy at H.C. Wainwright 08/13/21 Northland VYNE Therapeutics price target lowered to $6 from $12 at Northland VYNE VYNE Therapeutics / + 05/12/22 VYNE Therapeutics reports adjusted Q1 EPS (14c) vs (18c) last year 03/17/22 VYNE Therapeutics reports Q4 adjusted EPS (20c) vs (43c) last year

Earnings	Longeveron reports Q2 EPS (27c), consensus (23c) » 08:03 08/12/22 08/12 08:03 08/12/22 08:03 LGVN Longeveron $5.96 / -0.17 (-2.77%) Reports Q2 revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events LGVN Longeveron $5.96 / -0.17 (-2.77%) 05/13/22 Longeveron sees cash, equivalents funding operations into 1H24 05/09/22 Longeveron CEO Geoff Green to resign 04/13/22 Longeveron enters into CRADA with US Department of VA 04/05/22 Longeveron appoints Min as Chief Medical Officer LGVN Longeveron $5.96 / -0.17 (-2.77%) 03/24/22 Maxim Maxim starts Longeveron at Buy, sees stock as 'inexpensive later-stage play' 03/24/22 Maxim Longeveron initiated with a Buy at Maxim 01/05/22 EF Hutton Longeveron initiated with a Buy at EF Hutton LGVN Longeveron $5.96 / -0.17 (-2.77%) 05/13/22 Longeveron reports Q1 EPS (17c) vs. (18c) last year 03/11/22 Longeveron reports Q4 EPS (20c), two est. (25c) LGVN Longeveron $5.96 / -0.17 (-2.77%) 04/05/22 Fly Intel: After-Hours Movers 08:30 Today Longeveron - LGVN
Recommendations	Oppenheimer says Leafly valuation 'beginning to look attractive' » 08:02 08/12/22 08/12 08:02 08/12/22 08:02 LFLY Leafly $2.25 / -0.15 (-6.25%) Oppenheimer analyst Jason… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options LFLY Leafly $2.25 / -0.15 (-6.25%) 06/24/22 Leafly set to join Russell 3000, Russell 200 Indexes 04/14/22 Leafly names Deidre Boulware Chief People Officer 03/24/22 Leafly Holdings trading resumes 03/24/22 Leafly Holdings trading halted, volatility trading pause LFLY Leafly $2.25 / -0.15 (-6.25%) 07:32 Today Cowen Leafly price target lowered to $4 from $12 at Cowen 06:12 Today Benchmark Leafly price target lowered to $6.50 from $12.00 at Benchmark 05/20/22 Cowen Cowen starts Leafly with Outperform with its early mover advantage 05/20/22 Cowen Leafly initiated with an Outperform at Cowen LFLY Leafly $2.25 / -0.15 (-6.25%) 08/11/22 Leafly sees FY22 revenue $48M-$51M, three estimates $53.55M 08/11/22 Leafly reports Q2 EPS 37c, two estimates (12c) LFLY Leafly $2.25 / -0.15 (-6.25%) 05/20/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 05/18/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 09/07/22 Leafly LFLY Leafly $2.25 / -0.15 (-6.25%) 08/11/22 Leafly Holdings options imply 15.4% move in share price post-earnings 08/02/22 Leafly Holdings put volume heavy and directionally bearish 05/23/22 Largest borrow rate increases among liquid names 03/29/22 Leafly Holdings options imply 7.5% move in share price post-earnings
Earnings	Crinetics reports Q2 EPS (81c), consensus (67c) » 08:02 08/12/22 08/12 08:02 08/12/22 08:02 CRNX Crinetics $20.58 / -1.12 (-5.16%) Reports Q2 revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly CRNX Crinetics $20.58 / -1.12 (-5.16%) 08/04/22 Crinetics to present analyses of CRN04894 preclinical, Phase 1 results 05/25/22 Crinetics reports results from Phase 1 study of CRN04894 05/12/22 Crinetics expects cash to fund operations into second half of 2024 03/30/22 Crinetics announces results from MAD cohorts of CRN04777 study CRNX Crinetics $20.58 / -1.12 (-5.16%) 06/15/22 Evercore ISI Crinetics added to Best SMID 'Core' Ideas list at Evercore ISI 11/30/21 JMP Securities Crinetics initiated with an Outperform at JMP Securities 11/23/21 Evercore ISI Evercore starts 'rare endo treasure trove' Crinetics at Outperform 11/23/21 Evercore ISI Crinetics initiated with an Outperform at Evercore ISI CRNX Crinetics $20.58 / -1.12 (-5.16%) 05/12/22 Crinetics reports Q1 EPS (73c), consensus (58c) 03/30/22 Crinetics reports Q4 EPS (68c), consensus (62c) 13 Apr 21 Oct CRNX Crinetics $20.58 / -1.12 (-5.16%) 07/18/22 Fly Insider: Stitch Fix, Arcutis Bio among week's notable insider trades
Earnings	PepGen reports Q2 EPS ($1.23) vs ($6.03) last year » 08:01 08/12/22 08/12 08:01 08/12/22 08:01 PEPG PepGen $11.15 / -0.27 (-2.36%) Cash and cash equivalents… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events PEPG PepGen $11.15 / -0.27 (-2.36%) 07/22/22 PepGen appoints Caroline Godfrey to Scientific Advisory Board 06/16/22 PepGen expects cash to be sufficient for expenses into 1H25 06/16/22 PepGen announces anticipated upcoming milestones PEPG PepGen $11.15 / -0.27 (-2.36%) 05/31/22 Wedbush PepGen initiated with an Outperform at Wedbush 05/31/22 Stifel PepGen initiated with a Buy at Stifel 05/31/22 SVB Leerink PepGen initiated with an Outperform at SVB Leerink 05/31/22 BofA PepGen initiated with a Buy at BofA PEPG PepGen $11.15 / -0.27 (-2.36%) 06/16/22 PepGen reports Q1 EPS (18.94) vs. ($7.42) last year 06 May PEPG PepGen $11.15 / -0.27 (-2.36%) 05/31/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 05/07/22 Opening Day: Bausch + Lomb pops in public debut 08/15/22 2022 Biotech Summer Summit
Recommendations	System1 price target lowered to $19 from $26 at DA Davidson » 08:01 08/12/22 08/12 08:01 08/12/22 08:01 SST System1 $8.69 / +0.045 (+0.52%) DA Davidson analyst Tom… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options SST System1 $8.69 / +0.045 (+0.52%) 06/07/22 System1 set to join Russell 2000, Russell 3000 Indexes 05/13/22 Starboard takes stake in Humana, exits System1 04/19/22 System1 falls -33.8% 04/19/22 System1 falls -28.6% SST System1 $8.69 / +0.045 (+0.52%) 07:06 Today Benchmark System1 price target lowered to $13 from $15 at Benchmark 07/11/22 BofA BofA starts System1 at Buy with $12 price target 07/11/22 BofA System1 initiated with a Buy at BofA 04/26/22 Evercore ISI System1 initiated with an In Line at Evercore ISI SST System1 $8.69 / +0.045 (+0.52%) 08/11/22 System1 sees FY22 revenue $900M-$930M, consensus $997.34M 08/11/22 System1 reports Q2 revenue $220M, consensus $218.82M 04/04/22 System1 sees FY22 revenue $1B 04/04/22 System1 reports Q4 revenue $238.9M vs. $160.9M last year SST System1 $8.69 / +0.045 (+0.52%) 08/11/22 Fly Intel: After-Hours Movers 05/20/22 Proven algorithm says sell these stocks now 04/19/22 What You Missed On Wall Street This Morning 04/18/22 Fly Intel: After-Hours Movers 09/08/22 Consumer/Media/Entertainment Conference SST System1 $8.69 / +0.045 (+0.52%) 08/11/22 System1 options imply 10.1% move in share price post-earnings 07/29/22 Largest borrow rate increases among liquid names 07/22/22 Largest borrow rate increases among liquid names 07/21/22 Largest borrow rate increases among liquid names

Events

Earnings calls, analyst events, roadshows and more

Today at 08:30

Import Prices M/M: July 2022 Government Event
Today at 08:30

Import Prices Y/Y: July 2022 Government Event
Today at 08:30

Export Prices M/M: July 2022 Government Event
Today at 08:30

Export Prices Y/Y: July 2022 Government Event
SHPW
Today at 08:30

Shapeways - SHPW Conference Calls
BR
Today at 08:30

Broadridge - BR Conference Calls
LGVN
Today at 08:30

Longeveron - LGVN Conference Calls
PLXP
Today at 08:30

PLx Pharma - PLXP Conference Calls
RPID
Today at 08:30

Rapid Micro Biosystems - RPID Conference Calls
FLO
Today at 08:30

Flowers Foods - FLO Conference Calls

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	AYTU X AYTU Aytu BioPharma Spot Secondary Managers: Cantor Fitzgerald & Canaccord Priced at: $0.43 21.5M Shares BRBR X BRBR BellRing Brands Spot Secondary Managers: JPMorgan, Barclays, Citi, Goldman Sachs & Morgan Stanley Priced at: $23.50 14.8M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MDNA X MDNA Medicenna Therapeutics Spot Secondary Managers: Guggenheim, Bloom Burton Securities Priced at: $1.50 13.333M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial NUZE X NUZE NuZee Spot Secondary Managers: Maxim Priced at: $0.82 4.2M Shares PFLT X PFLT PennantPark Floating Rate Spot Secondary Managers: Morgan Stanley, Goldman Sachs, JPMorgan, Keefe Bruyette, RBC Capital & Truist Priced at: $12.40 4M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Tues	KRTX X KRTX Karuna Therapeutics Secondary Managers: Goldman Sachs & JPMorgan, Jefferies Priced at: $215.00 3.49M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MIRM X MIRM Mirum Pharmaceuticals Spot Secondary Managers: JPMorgan, SVB Securities & Evercore ISI, Raymond James Priced at: $23.00 3.48M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial TDW X TDW Tidewater Spot Secondary Managers: Morgan Stanley Priced at: $17.85 3.52M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Wed	ATNX X ATNX Athenex Secondary Managers: SVB Securities Priced at: $.75 35.3M Shares CINC X CINC CinCor Pharma Secondary Managers: Goldman Sachs, Morgan Stanley, Jefferies & Piper Sandler Priced at: $30.00 7.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial EVTC X EVTC Evertec Secondary Managers: JPMorgan Priced at: $32.00 6.26M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial LXU X LXU LSB Industries Secondary Managers: Goldman Sachs & UBS, Deutsche Bank, Jefferies, Piper Sandler, RBC Capital, BNP Paribas, Stifel Priced at: $13.00 13.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SOVO X SOVO Sovos Brands Secondary Managers: JPMorgan & Goldman Sachs, BofA, Credit Suisse, Barclays, UBS, Cowen, Piper Sandler, Stifel, William Blair, Telsey Advisory, Drexel Hamilton, Loop Capital Priced at: $14.00 8.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial VRNA X VRNA Verona Pharma Secondary Managers: Jefferies, Piper Sandler & Truist Priced at: $10.50 12.4M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial BNL X BNL Broadstone Net Lease Spot Secondary Managers: Goldman Sachs, BMO Capital, JPMorgan & Truist Priced at: $21.35 13M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial KIDS X KIDS OrthoPediatrics Spot Secondary Managers: Piper Sandler & Stifel Priced at: $55.00 750K Shares MAIN X MAIN Main Street Spot Secondary Managers: RBC Capital, UBS & Wells Fargo Priced at: $42.85 1.17M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Thurs	FRZA X FRZA Forza X1 IPO Managers: ThinkEquity Priced at: $5.00 3M Shares REBN X REBN Reborn Coffee IPO Managers: EF Hutton Priced at: $5.00 1.44M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial TGL X TGL Treasure Global IPO Managers: EF Hutton Priced at: $4.00 2M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CERE X CERE Cerevel Therapeutics Secondary Managers: Morgan Stanley, Goldman Sachs, Jefferies & Evercore ISI, Loop Capital, Seibert Williams Priced at: $35.00 7.25M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial INAB X INAB In8bio Secondary Managers: H.C. Wainwright Priced at: $1.90 5.39M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial PTLO X PTLO Portillo's Secondary Managers: Jefferies & Morgan Stanley, BofA, Piper Sandler Priced at: $23.75 8M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial INSP X INSP Inspire Medical Spot Secondary Managers: Goldman Sachs Priced at: $215.00 1M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Fri	No deals

Mon	No deals
Tues	BIAF X BIAF Bioaffinity Technologies IPO Managers: WallachBeth $6.00-6.25 1.285M Shares
Wed	No deals
Thurs	RANI X RANI Rani Therapeutics Secondary Managers: BofA, Cantor Fitzgerald & UBS, BTIG, H.C. Wainwright $ Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CERT X CERT Certara Spot Secondary Managers: Morgan Stanley $17.75-18.50 7M Shares
Fri	No deals

View All Syndicate Announcements »

GDS Holdings reports Q1 EPS (50c), consensus (25c)

OTHER BREAKING NEWS FROM THE FLY

Get Full Fly Access